Biosimilars Don't Deserve Unique Name, Group Tells FDA

Law360, New York (September 20, 2013, 8:02 PM EDT) -- A major generic pharmaceutical industry group told the U.S. Food and Drug Administration on Thursday not to give unique names to generic versions of biologic drugs, saying identical names for branded biologics and their biosimilars would not confuse customers or create drug safety concerns as some fear.

FDA-approved biosimilars — copies of medicine derived from living cells — should share the same international nonproprietary name, or INN, as the biologic products to which they refer, according to a citizen petition filed by the Generic Pharmaceutical Association....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.